The interview aims to explore the clinical and translational implications of the first-in-human Phase 1 results for CTX310, an in vivo CRISPR/Cas9 therapy targeting ANGPTL3. Discussion will focus on the durability and magnitude of triglyceride and LDL lowering after a single IV dose, the meaning of deep ANGPTL3 suppression, safety and tolerability considerations for systemic gene-editing approaches, the potential positioning of CTX310 for severe or refractory dyslipidemias, and the broader impact of one-time gene-editing therapies on cardiovascular disease prevention and long-term patient adherence.